Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
The Phase 2 TREASURE trial investigated the safety and efficacy of adding consolidative thoracic radiotherapy to atezolizumab maintenance in extensive-stage small cell lung cancer, revealing increased toxicity without survival benefit, unde
This review synthesizes recent phase I trial data on CD7 CAR-T therapies in relapsed/refractory AML, highlighting promising safety, high response rates, challenges with antigen loss relapse, and avenues for future research.
A four-year post hoc analysis of the TOPAZ-1 trial confirms that durvalumab combined with gemcitabine and cisplatin offers a long-term survival benefit with manageable safety as first-line treatment for advanced biliary tract cancer.
This article reviews evolving therapeutic sequences in advanced hepatocellular carcinoma, highlighting the integration of immune-based combinations, tyrosine kinase inhibitors, liver function preservation, and the emerging multidimensional
NEK9 upregulation in hepatocellular carcinoma promotes immune evasion by enhancing PD-L1 expression and recruiting suppressive myeloid cells. Novel NEK9 inhibitors synergize with PD-L1 blockade, remodeling the tumor microenvironment and imp
MSI-H/dMMR gastroesophageal adenocarcinoma showed high response rates to immune checkpoint inhibitors, including durable complete responses in locoregional disease that may support carefully selected nonoperative management.
This single-center cohort found high and durable checkpoint inhibitor responses in dMMR/MSI-H gastroesophageal adenocarcinoma, including complete responses in locoregional disease that may support carefully selected nonoperative management.
Extended follow-up of participants from 14 randomized trials found no excess self-reported serious adverse outcomes after type 1 diabetes immunotherapy, supporting continued long-term surveillance.
TROPHAMET found that first-line avelumab plus methotrexate achieved 96.2% hCG normalization in low-risk gestational trophoblastic tumors with manageable toxicity, no relapses at 41 months, and preserved fertility.
Extended follow-up from ASTRUM-005 shows serplulimab plus chemotherapy improves long-term survival in untreated extensive-stage small cell lung cancer, with manageable safety and encouraging patient-reported outcomes.
This retrospective study found that immune checkpoint inhibitors produced modest overall benefit in recurrent vulvar and vaginal carcinoma, but a small subset of patients had durable responses lasting months.
In advanced head and neck squamous cell carcinoma, pretreatment weight loss and low prognostic nutritional index were linked to shorter progression-free survival after immunotherapy, while baseline BMI was not predictive.
Recent studies demonstrate that combining the beta-cell-targeted conjugate GLP1-E2 with low-dose anti-CD3 therapy significantly delays type 1 diabetes onset by simultaneously reducing immune infiltration and mitigating beta-cell cellular st
A large claims-based study reveals pembrolizumab dominates immunotherapy prescribing for head and neck cancer, with minimal usage growth since FDA approval. Immune-related adverse events occurred in 41.2% of patients, linked to specific com
The NIVOLEP phase 2 trial demonstrates that perioperative nivolumab (neoadjuvant and adjuvant) combined with irreversible electroporation achieves 70.6% one-year local recurrence-free survival in BCLC A HCC patients with high recurrence ris
A nationwide French cohort study reveals that advanced NSCLC patients completing 2 years of pembrolizumab maintain excellent survival outcomes, with most remaining treatment-free and immunotherapy rechallenge being uncommon.
This retrospective study challenges the assumption that prior radiation limits immunotherapy effectiveness in recurrent endometrial and cervical cancers, finding no significant difference in response rates or survival outcomes based on recu
This review explores the breakthrough potential of Bovine Herpesvirus Type 1 (BoHV-1) as an oncolytic agent in Multiple Myeloma, highlighting its ability to induce mitochondrial apoptosis, reprogram the immunosuppressive bone marrow niche,
This review evaluates the optimal sequencing of radiotherapy and immunotherapy in advanced NSCLC, highlighting real-world evidence from the OCEANUS study favoring sequential over concurrent administration.
This review analyzes the 5-year overall survival outcomes of the CAPTAIN-1st trial, establishing camrelizumab plus chemotherapy as a long-term standard of care for recurrent or metastatic nasopharyngeal carcinoma.